Octagon Capital Advisors’s iTeos Therapeutics ITOS Stock Holding History

Octagon Capital Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-102,000	Closed	-$1.12M	–	41
2023 Q3	$1.12M	Sell	102,000 -494,000	-83%	-$6.32M	0.17%	37
2023 Q2	$7.89M	Hold	596,000	–	–	1.1%	16
2023 Q1	$8.11M	Buy	596,000 +151,000	+34%	+$2.71M	1.17%	17
2022 Q4	$8.69M	Buy	+445,000	New	+$8.7M	1.35%	17
2022 Q2	–	Sell	-450,776	Closed	-$14.5M	–	23
2022 Q1	$14.5M	Hold	450,776	–	–	3.14%	11
2021 Q4	$21M	Buy	+450,776	New	+$15M	4.08%	7

Other funds holding ITOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Octagon Capital Advisors's ITOS Position: Q4 2023 in Review

Octagon Capital Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 102,000 shares — an estimated $1.12M sold.

Octagon Capital Advisors first reported a position in ITOS in Q4 2021 and held it in 6 quarters. The position peaked at $21M in Q4 2021. 138 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

Octagon Capital Advisors reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
Octagon Capital Advisors sold 102,000 iTeos Therapeutics shares in Q4 2023, an estimated $1.12M.
Octagon Capital Advisors first reported a position in iTeos Therapeutics in Q4 2021 and held it in 6 quarters.
Octagon Capital Advisors's iTeos Therapeutics position peaked at $21M in Q4 2021.
138 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.